Skip to content

Lived-experience themes

1. Blame and moral judgement

T2D is frequently framed as self-inflicted, collapsing genetics, medication effects, food environment, stress, poverty and biology into individual choice. The international stigma consensus describes effects on mental health, self-care and care engagement (Speight 2024, PMID 38128969). Diabetes UK’s public stigma campaign reports blame, incorrect assumptions and internalised shame (Diabetes UK — “Diabetes stigma,” accessed 2026-08-30).

2. Work of treatment

Treatment consists of repeated small tasks: obtaining medicines, deciding what and when to eat, monitoring, titrating, attending eye/foot/kidney care and responding to illness. A systematic review of GLP-1RA/SGLT2 preferences found route, adverse effects, weight, hypoglycaemia and cost all influence choices (González-González 2021, PMID 34244276). Diabetes UK’s helpline explicitly includes emotional, social and practical difficulties (Diabetes UK — “Helpline,” accessed 2026-08-30).

3. Access and financial toxicity

Aggregate expenditure does not guarantee access: IDF estimated US$966 billion global diabetes expenditure in 2021, while cost studies show out-of-pocket burden is proportionally larger in lower-income settings (Sun 2022, PMID 34879977; Seuring 2015, PMID 25787932). ADA advocacy priorities include affordable medicines, technology and health coverage (ADA — “Advocacy,” accessed 2026-08-30).

4. Language in clinical care

Terms such as “non-compliant,” “poor control” and “failed” assign moral meaning to measurements or therapy response. Diabetes Australia’s position asks for clear, accurate, respectful, inclusive and non-judgmental language; the peer-reviewed international consensus similarly recommends ending blame (Diabetes Australia — “Position statements,” accessed 2026-08-30; Speight 2024, PMID 38128969).

A 21-clinician randomised pilot improved attitudes toward avoiding stigmatising language (Cohen d=1.67), but did not measure actual clinician language or patient experience and found no statistically significant between-group change in intentions (Joiner 2026, PMID 42579884). It establishes feasibility, not clinical effectiveness.

5. Remission: hope and pressure

DiRECT makes remission a real option for some early T2D, but five-year remission fell to 13% in the extension group (Lean 2018, PMID 29221645; Lean 2024, PMID 38423026). Presenting remission as universally achievable can convert a population trial result into personal blame when biology, duration, access or weight regain prevents it.

6. Treatment trade-offs are personal

Weight loss, injection frequency, gastrointestinal symptoms, urinary/genital effects, hypoglycaemia, cost and organ protection carry different importance for different people. Shared decisions require absolute benefits and burdens, not a one-dimensional HbA1c ranking (González-González 2021, PMID 34244276; Davies 2022, PMID 36148880).

7. Culture, family and continuity

Food and self-management occur within households and cultural systems. A systematic review of indigenous primary care emphasised culturally appropriate, community-linked models rather than simple transfer of standard programmes (Chopra 2022, PMID 36355789). IDF describes its member network as a way to ground global advocacy in local experience (IDF — “Regions & Members,” accessed 2026-08-30).

What is not established

  • These sources do not provide comparable prevalence for each theme.
  • Public campaigns may preferentially feature highly engaged participants.
  • English-language advocacy material underrepresents many settings.
  • As of 2026-08-30, a clinician-training pilot has measured attitudes, but patient-experience, engagement and biomedical outcomes remain untested (Joiner 2026, PMID 42579884).